ASX CODE: AHZ

Admedus ASX AHZ CardioCel 3D VascuCel regulatory approval Europe CE Mark

CE Mark approval paves way for Admedus to market tissue technology into Europe

Medical technology company Admedus (ASX: AHZ) has moved closer to increasing global sales of its Adapt tissue technology after receiving regulatory approval from European...
Cardiac medical device technologist Admedus (ASX: AHZ) has refined its worldwide sales strategy, signing up long-time operator Cardiva to distribute its ADAPT bio-scaffolding products in Spain and Portugal.

Admedus recruits Cardiva to distribute ADAPT tissue scaffolds in Spain, Portugal

Cardiac medical device technologist Admedus (ASX: AHZ) has refined its worldwide sales strategy, signing up long-time operator Cardiva to distribute its ADAPT bio-scaffolding products...
Admedus ASX AHZ vaccine research investment

Admedus attracts multimillion dollar investment for vaccine research

Medical technology company Admedus (ASX: AHZ) is on the brink of attracting at least $18 million to fund further research into its vaccine program. Admedus...
Admedus ASX AHZ biotech US sales network group purchasing organisation

Admedus delivers on shareholder pledge to expand US sales network

Biotech developer Admedus (ASX: AHZ) has signed a purchasing agreement with a major US-based group purchasing organisation (GPO) through its US subsidiary, Admedus Corporation...
Admedus ASX AHZ biotech tissue regeneration CardioCel VascuCel

Admedus adapts to growing tissue regeneration market in North America

Biotech company Admedus (ASX: AHZ) will soon be introducing its proprietary suite of products to Canadian consumers. The company received regulatory approval from regulators this...

RECENT POSTS

STOCK SUMMARY

HOT TOPICS

TRENDING POSTS